Biomea Fusion, Inc. Common Stock (BMEA) Stock
Key stats
- Market cap
- $44.40M
- Price / Earnings ratio
- -1.2x
- EPS (TTM)
- -$0.29
- Volume
- Loading
- 52-week high
- $2.24
- 52-week low
- $0.54
Source: third-party data provider, as of November 13, 2026
Compare with BMEA
Recent news
Biomea Fusion's BMF-650 Shows Up to 6.1% Weight Loss in Early GLP-1 Study
Biomea Fusion's BMF-650 Shows Up to 6.1% Weight Loss in Early GLP-1 Study
BMEA
After Golden Cross, Biomea Fusion, Inc. (BMEA)'s Technical Outlook is Bright
After Golden Cross, Biomea Fusion, Inc. (BMEA)'s Technical Outlook is Bright
BMEA
This Cleveland-Cliffs Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
This Cleveland-Cliffs Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
BMEA
Short Squeeze Specialists: 3 Stocks With the Expertise to Defy Bearish Expectations
Short Squeeze Specialists: 3 Stocks With the Expertise to Defy Bearish Expectations
BMEANews tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 33.80
- MACD 12/26/9
- -0.16
- EMA 9 of MACD
- -0.18
- MACD histogram
- 0.02
- SMA 50
- $1.19
- Price below SMA 50
- EMA 50
- $1.00
- Price below EMA 50
- SMA 200
- $1.34
- Price below SMA 200
- EMA 200
- $1.27
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 3 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news
Biomea Fusion's BMF-650 Shows Up to 6.1% Weight Loss in Early GLP-1 Study
Biomea Fusion's BMF-650 Shows Up to 6.1% Weight Loss in Early GLP-1 Study
BMEAAfter Golden Cross, Biomea Fusion, Inc. (BMEA)'s Technical Outlook is Bright
After Golden Cross, Biomea Fusion, Inc. (BMEA)'s Technical Outlook is Bright
BMEAThis Cleveland-Cliffs Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
This Cleveland-Cliffs Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
BMEAShort Squeeze Specialists: 3 Stocks With the Expertise to Defy Bearish Expectations
Short Squeeze Specialists: 3 Stocks With the Expertise to Defy Bearish Expectations
BMEA
Looking for the next meme stock? These stocks are short-squeeze targets
Looking for the next meme stock? These stocks are short-squeeze targets
BMEA
7 Short-Squeeze Stocks That Could Send the Bears Into Panic-Mode
7 Short-Squeeze Stocks That Could Send the Bears Into Panic-Mode
BMEA
Short Sellers Think These Stocks Will Tank in 2024. Investors Can Bet Otherwise.
Short Sellers Think These Stocks Will Tank in 2024. Investors Can Bet Otherwise.
BMEANews tone: automated (AI) classification of the article's content, not a price prediction.
About Biomea Fusion, Inc. Common Stock
Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Michael J. M. Hitchcock Ph.D. | Interim CEO & Director | 1950 |
| Mr. Ramses M. Erdtmann | Co-Founder, President, COO & Director | 1963 |
| Mr. Heow Tan | Chief Technical & Quality Officer | 1959 |
| Caroline Perez- Dupont J.D. | Senior Vice President of Legal | — |
| Dr. Thorsten Kirschberg Ph.D. | Executive Vice President of Research | 1970 |
| Dr. Stephan Morris M.D. | Chief Development Officer | — |
| Mr. Ravi Upasani Ph.D. | Executive Vice President of Intellectual Property | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 33.80
- MACD 12/26/9
- -0.16
- EMA 9 of MACD
- -0.18
- MACD histogram
- 0.02
- SMA 50
- $1.19
- Price below SMA 50
- EMA 50
- $1.00
- Price below EMA 50
- SMA 200
- $1.34
- Price below SMA 200
- EMA 200
- $1.27
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
3 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $4.00
- Average
- $7.00
- High
- $10.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -30.3 | +0.7 | +5.8 | -14.0 | +40.0 | -26.1 | -50.8 | -7.6 |
